Sorry, I remember now. Should I do something, is it okay as is.

I think we also also to provide some suggested talking points about how these findings relate to the IARC evaluation in case Manisha gets asked questions at her presentation. Here is what I am thinking. What do you think. Once we agree, Laura can suggest this to Manisha and the rest of the group.

1) These studies were all considered for the IARC Monograph on glyphosate. These combined data show an excess for NHL as did the U.S. and Canadian studies separately.
2) Pooling provided larger numbers and opportunities to perform analyses not possible in the individual studies, e.g., by histologic type.
3) A positive trend for NHL occurred with days per year and cumulative days of use of glyphosate, but not for duration (years) of use.
4) There were hints of differences for these use metrics among the histologic types, although they were not statistically different across the histologic types.
3) Adjustment for use of 2,4-D, dicamba, and malathion reduced the ORs. Although excesses still occurred, they were no longer statistically significant.
4) These data, although far from conclusive, suggest that the association between glyphosate and NHL might differ by histologic type. FL was not linked to glyphosate at all.
Manisha can send to Kurt, and Jennifer can send to her IARC press contact.

**From:** Beane-Freeman, Laura (NIH/NCI) [E]
**Sent:** Wednesday, August 26, 2015 4:33 PM
**To:** Blair, Aaron (NIH/NCI) [V]
**Cc:** Zahm, Sheila (NIH/NCI) [C]
**Subject:** RE: Glyphosate and NHL presentation [ISEE Conference]

I thought that we were going to do that here through Jennifer L and her contact with the IARC communications person?

**From:** Blair, Aaron (NIH/NCI) [V]
**Sent:** Wednesday, August 26, 2015 4:33 PM
**To:** Pahwa, Manisha; Beane-Freeman, Laura (NIH/NCI) [E]; ...; Zahm, Sheila (NIH/NCI) [C]
**Cc:** Harris, Shelley; Demers, Paul
**Subject:** RE: Glyphosate and NHL presentation [ISEE Conference]

Manisha,

Thanks. Have any of the other coauthors weighed in about notifying IARC in advance?

I think sending them the abstract you submitted and the final slides before the ISEE meeting just for their information might be useful. They should probably go to Kurt Straif, who is head of the Monograph program.

Aaron

**From:** Pahwa, Manisha
**Sent:** Wednesday, August 26, 2015 4:22 PM
**To:** Blair, Aaron (NIH/NCI) [V]; ...; Zahm, Sheila (NIH/NCI) [C]
**Cc:** Harris, Shelley; Demers, Paul
**Subject:** RE: Glyphosate and NHL presentation [ISEE Conference]

Hi Aaron,

Yes, absolutely! I'm now revising the slides according to the comments that I have received so far from you, John S., John M., and Laura. A few others have responded but with no comments. I will send everyone a revised slide deck this evening. Hopefully, this will allow enough time to share the slides with others at NCI. If any further changes need to be made, I will address them right away and send the final slides to our co-authors prior to my presentation. Does that sound like a good plan?
To address the questions in your earlier e-mail, the abstract does not appear on the ISEE website or in the conference program. I can prepare a final version of the slides for IARC if you would like. I agree that it would be best for me to not deal with any potential press while at the conference, but I will develop “talking points” that could assist with responses to interviews that may arise following the meeting. I’ll draft talking points today and disseminate to the group along with my revised slides.

Thanks to you and everyone for your rapid and helpful feedback!

Speak again soon,

Manisha
Thank you, and please let me know if you have any questions or would like additional information.

Manisha

Manisha Pahwa, Research Associate
Occupational Cancer Research Centre, Cancer Care Ontario
620 University Avenue, Toronto, Ontario, M5G 2L7
www.occupationalcancer.ca

This e-mail message (and any attachments) may contain confidential and/or privileged information for the sole use of the intended recipient. Any review or distribution by anyone other than the person for whom it was originally intended is strictly prohibited. If you have received this e-mail in error, please contact the sender and delete all copies. Opinions, conclusions or other information contained in this e-mail may not be that of the organization.